CHALLENGES OF HEMATOLOGICAL GENOMIC ANALYSES

The use of Next-Generation Sequencing (NGS) has revolutionized the cancer diagnosis by providing high-throughput and increasingly cost-efficient diagnostic technologies. Healthcare institutions worldwide are using NGS to detect multiple cancer-associated alterations in routine diagnostics.

The Myeloid Solution by SOPHiA GENETICS is a molecular diagnostic application that bundles the analytical power of SOPHiA AI with a capture-based target enrichment kit and full access to SOPHiA DDM platform.

It is the first CE-IVD marked capture-based solution, expertly designed to accurately characterize the complex mutational landscape of the major hematological disorders associated with leukemia, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).

In the first part of this webinar, Dr. Alexander Kurze will present the clinical-grade performance of the Myeloid Solution by SOPHiA GENETICS, matching diagnostic requirements.

In the second part of the webinar, Dr. Céline Bourgne will show how she evaluated, tested and implemented the Myeloid Solution by SOPHiA GENETICS. She will also discuss how this solution has helped her to establish quickly an accredited diagnostic workflow and how it improved patients’ diagnosis and prognosis.

Dr. Celine Bourgne has established and validated the sequencing workflow for the hematological laboratory in the Clermont-Ferrand University Hospital, which belongs to the National Cancer Institute network of 28 hospital molecular genetics platforms in France.